NRF1-enhanced miR-4458 alleviates cardiac hypertrophy through releasing TTP-inhibited TFAM


Growing evidence suggests the crucial role of microRNAs (miRNAs) in regulating basic cell functions, and therefore participating in the pathologic development of diverse human diseases, including cardiac hypertrophy. Herein, we explained that miR-4458 was distinctly stimulated in Ang II-stimulated hypertrophic H9c2 cells. Intriguingly, miR-4458 inhibition led to exacerbated hypertrophic phenotypes in Ang II-treated H9c2 cells. In addition, the compensatory upregulation of miR-4458 in Ang II-treated H9c2 cells was ascribed to its transcriptional enhancement by NRF1, a transcription factor previously identified to be activated in early cardiac hypertrophy. Moreover, we discovered that miR-4458 served as a negative modulator in cardiac hypertrophy by prompting TFAM, a well-recognized myocardial protective protein. TTP, a RBP that always leads to degradation of recognized mRNAs, was predicted to interact with both miR-4458 and TFAM mRNA. Importantly, we verified that miR-4458 facilitated TFAM expression in cardiomyocytes by directly targeting TTP and releasing TTP-destabilized TFAM mRNA. On the whole, these findings demonstrated that NRF1-induced miR-4458 boosted TFAM via targeting TTP to dampen the exacerbation of cardiac hypertrophy, which indicates miR-4458 as a promising biomarker for the cardiac hypertrophy treatment.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Figure 1.
Figure 2.
Figure 3.
Figure 4.


  1. Aaronson KD, Sackner-Bernstein J (2006) Risk of death associated with nesiritide in patients with acutely decompensated heart failure. Jama 296:1465–1466

  2. Anant S, Houchen CW (2009) HuR and TTP: two RNA binding proteins that deliver message from the 3' end. Gastroenterology 136:1495–1498

  3. Barry SP, Townsend PA (2010) What causes a broken heart—molecular insights into heart failure. Int Rev Cell Mol Biol 284:113–179

  4. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233

  5. Bartel DP, Chen CZ (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5:396–400

  6. Bartz RR, Suliman HB, Piantadosi CA (2015) Redox mechanisms of cardiomyocyte mitochondrial protection. Front Physiol 6:291

  7. Bhawe K, Roy D (2018) Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression. Cell Oncol (Dordr) 41:465–484.

  8. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772–2786

  9. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613–618

  10. Cirillo D, Marchese D, Agostini F, Livi CM, Botta-Orfila T, Tartaglia GG (2014) Constitutive patterns of gene expression regulated by RNA-binding proteins. Genome Biol 15:R13

  11. Divakaran V, Mann DL (2008) The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103:1072–1083

  12. Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, Giacca M (2012) Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492:376–381

  13. Flemming A (2014) Heart failure: targeting miRNA pathology in heart disease. Nat Rev Drug Discov 13:336

  14. Greco CM, Condorelli G (2015) Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nat Rev Cardiol 12:488–497

  15. Guo J, Qu H, Chen Y, Xia J (2017) The role of RNA-binding protein tristetraprolin in cancer and immunity. Med Oncol 34:196

  16. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B (2013) Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:1420–1432

  17. Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370–1380

  18. Ho YL, Wu CC, Lin LC, Huang CH, Chen WJ, Chen MF, Liau CS, Lee YT (1998) Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: effect of the left ventricular hypertrophy. Cardiology 89:52–58

  19. Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, Fujiwara T, Hamasaki N, Takeshita A, Sunagawa K, Tsutsui H (2005) Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation 112:683–690

  20. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120:623–634

  21. Kloosterman WP, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441–450

  22. Kunkel GH, Chaturvedi P, Theilen N, Nair R, Tyagi SC (2017) Mechanism of TFAM mediated cardiomyocyte protection. Can J Physiol Pharmacol.

  23. Kuppusamy KT, Sperber H, Ruohola-Baker H (2013) MicroRNA regulation and role in stem cell maintenance, cardiac differentiation and hypertrophy. Curr Mol Med 13:757–764

  24. Liu CH, Lv DS, Li M, Sun G, Zhang XF, Bai Y (2017) MicroRNA-4458 suppresses the proliferation of human lung cancer cells in vitro by directly targeting Lin28B. Acta Pharmacol Sin 38:1297–1304.

  25. Liu F, Li N, Long B, Fan YY, Liu CY, Zhou QY, Murtaza I, Wang K, Li PF (2014) Cardiac hypertrophy is negatively regulated by miR-541. Cell Death Dis 5:e1171–e1171

  26. Liu X, Wang J, Zhang G (2019) miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer. J Cell Biochem.

  27. McKinsey TA, Kass DA (2007) Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 6:617–635

  28. Nomura S, Satoh M, Fujita T, Higo T, Sumida T, Ko T, Yamaguchi T, Tobita T, Naito AT, Ito M, Fujita K, Harada M, Toko H, Kobayashi Y, Ito K, Takimoto E, Akazawa H, Morita H, Aburatani H, Komuro I (2018) Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure. Nat Commun 9:4435

  29. Qin Y, Cheng C, Lu H, Wang Y (2016) miR-4458 suppresses glycolysis and lactate production by directly targeting hexokinase2 in colon cancer cells. Biochem Biophys Res Commun 469:37–43

  30. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov.

  31. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, Hu X, Wang DZ (2014) Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 114:1585–1595

  32. Tang D, Sun B, Yu H, Yang Z, Zhu L (2015) Tumor-suppressing effect of miR-4458 on human hepatocellular carcinoma. Cell Physiol Biochem 35:1797–1807

  33. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K, Thum T (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3:1078–1078

  34. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20:515–524

  35. van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117:2369–2376

  36. van Rooij E, Olson EN (2012) MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11:860–872

  37. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, Hou N, Guo S, Wang Y, Fan K, Zhan D, Zha L, Cao Y, Li Z, Cheng X, Zhang Y, Yang X (2012) Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 22:516–527

  38. Wang J, Yang X (2012) The function of miRNA in cardiac hypertrophy. Cell Mol Life Sci 69:3561–3570

  39. Yan M, Chen C, Gong W, Yin Z, Zhou L, Chaugai S, Wang DW (2014) miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. Cardiovasc Res.

  40. Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL, Nerbonne JM (2014) Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129:1009–1021

  41. Zhang M, Jiang Y, Guo X, Zhang B, Wu J, Sun J, Liang H (2019a) Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN/AKT pathway.

  42. Zhang Q, Wang F, Wang F, Wu N (2019b) Long noncoding RNA MAGI1-IT1 regulates cardiac hypertrophy by modulating miR-302e/DKK1/Wnt/beta-catenin signaling pathway. J Cell Physiol.

Download references


Thanks to all the participators.

Author information

Correspondence to Jun Feng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Editor: Tetsuji Okamoto

Electronic supplementary material

Figure S1

(A) ANP, BNP and β-MHC expression in mice model was assessed in qRT-PCR. (B) Western blot assayed ANP, BNP and β-MHC protein in mice model. (C) MiR-4458 expression in mice model was tested in qRT-PCR. (D) NRF1 expression in mice model was examined in qRT-PCR. (E) Overexpression efficacy of TFAM in H9c2 was confirmed via qRT-PCR. (F) Overexpression efficacy of miR-4458 in H9c2 was testified through qRT-PCR. * P < 0.05, ** P < 0.01 (PNG 295 kb)

High Resolution Image (TIF 7.70 MB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, M., Zhang, J., Jin, X. et al. NRF1-enhanced miR-4458 alleviates cardiac hypertrophy through releasing TTP-inhibited TFAM. In Vitro Cell.Dev.Biol.-Animal (2020) doi:10.1007/s11626-019-00419-3

Download citation


  • Cardiac hypertrophy
  • MiR-4458
  • NRF1
  • TFAM
  • TTP